ALPHA — Pharnext SCA Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual income statement for Pharnext SCA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | — | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.69 | 0.253 | 0.04 | 0.085 | 0.001 |
Cost of Revenue | |||||
Gross Profit | — | — | 0.025 | 0.059 | -0.079 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 20.6 | 20.3 | 19 | 22.9 | 27.8 |
Operating Profit | -17.9 | -20 | -18.9 | -22.9 | -27.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -21.3 | -23.3 | -21.6 | -30.6 | -38.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -21.3 | -23.3 | -21.6 | -30.6 | -38.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -21.3 | -23.3 | -21.6 | -30.6 | -38.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -21.3 | -23.3 | -21.6 | -30.6 | -38.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -426,336,320,000 | -388,486,150,000 | -308,058,057,143 | -255,147,025,000 | -549,227,200,000 |
Dividends per Share |